Comparison of HCV Prevalence in Pakistan and Iran; An Insight into Future

Muhammad Sohail Afzal; Tahir Ahmed; Najam us Sahar Sadaf Zaidi

doi:10.5812/hepatmon.11466

Comparison of HCV Prevalence in Pakistan and Iran; An Insight into Future

authors:

Muhammad Sohail Afzal ^{1
, *} , Tahir Ahmed ¹ , Najam us Sahar Sadaf Zaidi ¹

1 Atta ur Rahman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan

Hepatitis Monthly: Vol.14, issue 1; e11466

published online: January 12, 2014

article type: Letter

received: April 9, 2013

accepted: April 28, 2013

DOI: https://doi.org/10.5812/hepatmon.11466

how to cite: Afzal M S, Ahmed T, Zaidi N U S S. Comparison of HCV Prevalence in Pakistan and Iran; An Insight into Future. Hepat Mon. 2014;14(1):e11466. https://doi.org/10.5812/hepatmon.11466.

Keywords

Hepatitis C Infection Prevalence Awareness Health Promotion

Acknowledgements

Footnotes

Implication for health policy/practice/research/medical education:Currently the prevalence of HCV is low in Iran. Viral spread is going to increase with the passage of time. Barbers and dentists practice procedures should also be standarized with HCV safety guidelines. It is highly needed to start massive awareness campaign in Iran against HCV to educate general population to contain the viral spread over time.
Authors’ Contribution:Study concept, design and manuscript drafting: Muhammad Sohail Afzal, Tahir Ahmed, Najam us Sahar Sadaf Zaidi.
Financial Disclosure:There is no financial interest related to the material in the manuscript.
Funding/Support:This study was supported by Higher Education Commission Pakistan and National University of Sciences and Technology, Islamabad, Pakistan.

References

1.
Shakeri MT, Nomani H, Ghayour Mobarhan M, Sima HR, Gerayli S, Shahbazi S, et al. The prevalence of hepatitis C virusin mashhad, iran: a population-based study. Hepat Mon. 2013;13(3). ee7723. [PubMed ID: 23745128]. https://doi.org/10.5812/hepatmon.7723.
2.
Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002;17(10):1092-7. [PubMed ID: 12201870].
3.
Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, Shafi T, et al. Sequence and structural analysis of 3' untranslated region of hepatitis C virus, genotype 3a, from pakistani isolates. Hepat Mon. 2013;13(5). ee8390. [PubMed ID: 23922562]. https://doi.org/10.5812/hepatmon.8390.
4.
Safi SZ, Afzal MS, Waheed Y, Butt UJ, Fatima K, Pervez Y, et al. Seroprevalence of hepatitis C and human immunodeficiency viruses in blood donors of northwestern Pakistan. Asian Biomed. 2011;5(3):389.
5.
Waheed Y, Saeed U, Anjum S, Afzal MS, Ashraf M. Development of Global Consensus Sequence and Analysis of Highly Conserved Domains of the HCV NS5B Prote in. Hepat Mon. 2012;12(9). ee6142. [PubMed ID: 23087757]. https://doi.org/10.5812/hepatmon.6142.
6.
Alavian SM. Triangular clinics: The way of the future. Hepat Mon. 2005;5(3):51-2.
7.
Afzal MS, Tahir S, Salman A, Baig TA, Shafi T, Zaidi NU, et al. Analysis of interleukin-10 gene polymorphisms and hepatitis C susceptibility in Pakistan. J Infect Dev Ctries. 2011;5(6):473-9. [PubMed ID: 21727647].
8.
Afzal MS, Anjum S, Zaidi NU. Effect of Functional Interleukin-10 Polymorphism on Pegylated Interferon-alpha Plus Ribavirin Therapy Response in Chronic Hepatitis C Virus Patients Infected With 3a Genotype in Pakistani Population. Hepat Mon. 2013;13(6). ee10274. [PubMed ID: 24032042]. https://doi.org/10.5812/hepatmon.10274.

comments